Cardiovascular disorders have been one of the mainstay causes for the estimated rise in the incidences of mortality. In earlier times, treatment approach was initiated with statin therapy even though there were high reports of adverse events and failure to attain the target lipid concentration. In 2003, Proprotein Convertase subtilisin/kexin 9 was found to be responsible for the degradation and inactivation of LDL receptors. Ever since the concept was introduced, many researches have been conducted in this field for a better control in lipid management. Alirocumab was approved by FDA in the year 2015 as a PCSK9 inhibitor indicated for heterozygous familial hypercholesterolemia. The purpose of this review is to compile the available information on the LDL-C reduction capacity of Alirocumab in combination with statins and simultaneous cardiovascular risk reduction. It also aims at providing an evidential safety data associated with Alirocumab use. Alirocumab is presently available in doses of 75 and 150mg subcutaneous injections once every two weeks. It is a monoclonal antibody directed against PCSK9 and evidential data provides an estimate of about 54% reduction in LDL-C concentrations. The application of Alirocumab as add on therapy to statins is the area of interest and the data suggests that there is a significant higher rate of LDL-C reductions in turn leading to a noteworthy cardiovascular risk reduction. However the appropriate dose of statins to incorporate a PCSK9 inhibitor requires further hypotheses. Additionally the safety profile of Alirocumab was found to be comparable with placebo or the control.
INTRODUCTION
Cardiovascular diseases are the prime cause of morbidity and mortality worldwide and research has been done to modify and for the prevention of its risk factors. It is well known and documented that, lowering of LDL cholesterol is the mainstay of therapy in the primary and secondary prevention of CVD. 1 Presently statins remain the cornerstone of lipid lowering therapy but conversely, there is widespread incidence of failure to achieve target lipid lowering goal even with the maximally tolerated dose of statins. This can be attributed to statin intolerance such as an injection site reaction, myalgia and myositis. [2] [3] Recent trends in medical diagnosis have led to the clear concept of the residual cholesterol levels and the high risk of cardio vascular events. To attain a better control and lowering of LDL-C, a new group of drugs called PCSK9 inhibitors have been recently approved by the FDA and the European Medical Agencies. 4 PCSK9 inhibitors have been playing an overriding therapeutic role in the lipid homeostasis, ever since it was discovered in 2003. It is a proprotein found profusely in the human blood and moreover it has been found to be responsible for the degradation of LDL receptors and thereby increasing blood concentration of LDL-C, attributing to higher risk of adverse vascular events. 5 It is self-cleaved, secreted and tightly binds to the EGF-A-like domain of the LDLR which in turn causes the LDLR recycling leading to the down regulation of LDLR activity. [6] [7] Lipid metabolism is also caused by degradation of endosomes and lysosomes in the cell surface. Furthermore, there is a link found between atherosclerosis and PCSK9 as vascular smooth muscle cells secrete PCSK9, which causes cutback in LDLR expression and LDL-C uptake of human and murine macrophages, ensuing vascular lipid build up and oxidation. 8 Loss of function mutations in LDLR, heterozygous mutation in ApoB affecting the LDL receptor binding domain of ApoB or heterozygous gain-of-function mutations in PCSK9, are the identified genetic causes of Heterozygous Familial Hypercholesterolemia. Homozygous FH on the other hand, is a result of homozygous or frequently, from compound heterozygous mutations in either the LDLR or ARH genes. Additionally it has been proven that the incidence of CVD is considerably lower in patients having LOF mutation of PCSK9. 9 These present the ground data that offer strong rationale supporting the use of PCSK9 inhibitors. Alirocumab is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, available in doses of 75 mg administered subcutaneously Q2W and the maximum dosage is 150 mg Q2W. 10 The primary objective of this review is to compile the available information on the efficacy of Alirocumab in combination with statins, on LDL-C reduction and thus cardiovascular risk reduction, the secondary objective being to provide an evidential data on the safety associated with the use of Alirocumab.
MATERIALS AND METHODS

Literature search
For the selection of studies, the approach used was to primarily choose randomized controlled trials that assess the PCSK9 inhibitors' efficacy when used in combination with statins, with or without Ezetimide and also the study should provide the data on the safety and adverse effect profile of Alirocumab. PubMed, BMC, Clinical key, Scopus, Science direct and the Cochrane CENTRAL were the databases that were searched, while using the search terms; 'PCSK9 inhibitors' , 'PCSK9' , ' AMG 145' , ' Alirocumab' , 'CVD risk reduction' and 'statins' . The finally extracted references were manually checked and the abstracts and non-English papers were excluded.
Study selection
The databases generated 790 articles and out of them 721 were excluded as they were abstracts, protocols or forum discussions. On further refining, 90 studies were excluded due unavailability of full text articles and duplication. After the final scrutiny, 9 studies met with the inclusion criteria and hence were included in the review. All subjects included in the studies were screened for the eligibility criteria and being on a baseline statins with or without Ezetimibe was a must, but should have had a LDL-C concentration of ≥ 70mg/dl for those who had CVD and ≥100mg/dl for those who had coronary artery disease risk equivalents like diabetes mellitus with other risk factors or chronic kidney disease. Across the 9 studies, 2052 patients were randomized and treated: the intervention arm being of Alirocumab (50, 75 or 150mg) and the control arm consisting of placebo, Ezetimibe or doubling the statin dose. Characteristics of included studies are shown in Table 1 .
RESULTS
LDL-C Reduction
Comparison of Alirocumab with other alternatives and its mean percentage changes in LDL-C reduction is shown in Table 2 . The study conducted by Kereiakes et al. 11 in the ITT analysis; the mean percent change of LDL-C from baseline to the 24 th week for Alirocumab was −48.2% and −2.3% for placebo. On the other hand, for the on-treatment analysis, it was found −50.7% and −0.8% respectively (P≤ .0001). For the other lipid parameters, there was a significant reduction observed at the 24 th week with Alirocumab (P ≤.0001 vs placebo). For non-HDL-C reduction it was observed −39.1% for Alirocumab and −1.6% for placebo. Others include apolipoprotein B −36.7% vs −0.9%, total cholesterol −27.9% vs −2.9 and lipoprotein (a) −20.5 −5.9%. Similarly in the study conducted by Teramoto et al. 12 Alirocumab resulted in a dosedependent achievement in a ≥50% reduction in LDL-C which was not observed in any of the subjects in the placebo arm. Significant decline in the concentrations of total cholesterol, non HDL-C and apolipoprotein B were also observed (p <0.0001). Additionally as per Shahawy et al. On top of the above outcomes, in the study by Cannon et al. 16 the assessment of the primary end point was 250.6 plus 1.4% {mean plus standard error (SE) decrease in LDL-C at the 24 th week} in the interventional arm and 220.7 plus 1.9% in the Ezetimibe arm while both the arms were on a background of maximally tolerated statin therapy, with a statistically significant difference of the means + SE between groups of 229.8 (95% CI 234.4 to 225.3, P , 0.0001). Some studies had to increase the dose of Alirocumab from 75 mg to 150mg at week 12 if the LDL-C ≥ 70mg/dl at week 8. [16] [17] Subjects treated with add on Alirocumab showed higher reduction in LDL-C as compared to control arm in all the study pools. In addition to this, there was no association found between the type and dose of baseline statins and percentage change of LDL-C for Alirocumab and control arm. It was also found that the measured and the calculated values of LDL-C were consistent with each other. Efficacy of Alirocumab over time showed early and sustained reduction of LDL-C as compared to placebo and the reduction was found to be comparable. Teramoto et al. used three doses of Alirocumab i.e 50mg, 75mg and 150mg in their multiple dose study and it showed significant dose dependent LDL-C reduction. When the dose of Alirocumab was increased after week 12, additional decrease in the LDL-C was documented.
LDL-C goal attainment
The proportion of patients achieving the target LDL-C was significantly larger in Alirocumab arm as compared to placebo arm. Most of the patients (>80%) having high or very high cardiovascular risk achieved LDL-C <70 mg/dl and <100 mg/dl respectively in Alirocumab arm 18 and this proportion was much higher than any other add-on therapies of lipid lowering agents like Ezetimibe and doubling of statin dose. However there was association found between proportion of patients attaining the LDL goal and statin dose. The multiple dose study also showed a dose dependent increase in the proportions of patients achieving ≥50% LDL-C reduction. 12 Other lipid parameters There were marked reductions in non HDL-C, Apolipoprotein B, Lipoprotein (a), Triglycerides and total cholesterol associated with Alirocumab as compared to placebo or other controls. Relative to other parameters, triglycerides had a lesser degree of change when attributed to Alirocumab. Some studies also showed that the difference in Triglyceride levels between Alirocumab and Ezetimibe arm was not statistically significant. 13, 15 Modest HDL-C elevation was also documented attributed to Alirocumab as compared to control. Other lipid parameters are shown in Table 3 .
Safety Summary
The safety and adverse events associated with Alirocumab extracted from various studies are represented in Table 4 . The treatment emergent adverse and serious adverse events were found to be comparable between intervention and control arm. In the study conducted by Kereiakes et al. the incidence of TESAEs and TEAEs were comparable between the groups. TEAEs leading to discontinuation or death were also reported. 5.3% in the interventional group and 2.8% among the placebo arm, which demonstrated reports of local injection site reactions. Additionally, allergic reactions were reported in 8.7% subjects receiving Alirocumab and 6.5% for subjects receiving placebo patients. However, in the study by Teramoto et al. there were no reports of serious adverse events or drug discontinuations. As per the study concluded by Shahawy et al. local injection-site reactions were reported about 2.5% in the interventional group and 0.8% in the Ezetimibe group for the first year, whereas it was reported about 0.2% in the interventional group for the second year. In the study by Bays et al. TEAEs were reported in 65.4% of subjects with interventional add-on therapy, however discontinuation was reported in 6.7% of these subjects. Overall, TESAEs were reported for 5.4% of patients of which two subjects died during the study who were on Ezetimibe group. 18 Additionally in the study by Cannon et al. the rate of TEAE leading to death was reported in 0.4% of subjects in the interventional group and in 1.7% of subjects in the Ezetimibe group. 18.8% of patients in interventional arm and 17.8% of subjects in Ezetimibe arm reported serious adverse events. However, a higher proportion of TEAEs leading to discontinuation was observed in the interventional arm (7.5% to 5.4%). 16 In the study conducted by Leiter et al. cardiovascular events were reported in 8.8% and 2.6% of subjects with DM and 5.4% and 6.7% of subjects without diabetes mellitus for the interventional and Ezetimibe arms respectively. [11] . Ginsberg et al [12] ( Leiter et al [13] ( [14] (2016) 
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DISCUSSION
The Food and Drug Administration, USA approved Alirocumab in the year 2015 for use in patients with clinical ASCVD and HeFH receiving maximally tolerated statin therapy and still requiring further LDLlowering. The dose of Alirocumab being 75 mg administered subcutaneously once every 2 weeks, adjusted upto 150mg subcutaneously once every 2 weeks based on the patients Lipid control. 21 However, since the recent approval of the drug in the market, further epidemiological data may be necessary to elucidate the risk versus benefit outcomes of Alirocumab use. It may be applied in instances where only limited options remain in the control of dyslipidemias and in patients with statin intolerance. Data and clinical outcomes are implicating the efficacy of Alirocumab in reduction of LDL being far greater than any of the existing lipid lowering therapies. Studies have shown that monotherapy of PCSK9 inhibitors cause 50-58% of LDL-C reduction. 22 This review briefs on the hypothesis that the LDL-C lowering capability of Alirocumab is further amplified when used with statins. To justify this, Stroes E et al. 32 studied the effect of monotherapy of Alirocumab on LDL reduction and it was found to be -51.7% and -53.5% for 150mg Q4W and 75mg Q2W respectively, whereas Teramoto et al. 12 studied the effect of same but in combination with background statins and found that the LDL reduction from baseline was -62.3% and -71.7% for the same doses. Hence, when the patients' cholesterol level is poorly controlled by baseline low, moderate or high intensity statin, it can be brought well within the range by adding Alirocumab. 23 It was also found that, LDL-C reduction was increased in Alirocumab arm irrespective of and unaffected by the dose of statin, which indicates that even though Statins as well as PCSK9 monoclonal antibody therapy causes upregulation of LDL receptors, their mechanisms for LDL reduction are different. 23 Studies done on add on Alirocumab with different doses of statins showed that there is a lesser degree of reduction in LDL-C in higher doses of statin as compared to their lower doses. This effect can be attributed to the fact that statin treatment increases the activity of sterol regulatory element binding protein 2(SREBP-2) causing amplification of PCSK9 expression leading to reduced uptake of LDL-C and this happens dose dependently. But this effect is not significant with Ezetimibe. 24 LDL reduction is attained at 4 weeks and remains considerably constant through 12 and 24 weeks, 25 and this is consistent with the study done by Shahawy et al. 13 which showed constant LDL reduction for upto 2 years. LDL reduction is shown to be accompanied by percent and absolute decrease in calculated 10 year cardiovascular risk calculated by both ACC/AHA and NIH calculators. 25 In statin intolerance, Ezetimibe is the recommended alternative to statins but causes only 15-20% of LDL reduction. 26 In the absence of statins, a higher magnitude of LDL reduction is required and this need can be addressed by Alirocumab. 27 Majority of patients with ASCVD and/or HeFH in Alirocumab arm, reached their target LDL levels in this pooled data. The additional LDL-C reduction caused by increasing the dose of Alirocumab from 75mg to 150mg at week 12 was around 14% in COMBO II and FH 1 study. The dose increase was more likely done in patients having higher baseline LDL-C. 18, 19, 28 Addition of Ezetimibe to baseline statin showed additional 12-18% reduction of LDL but only a 6% decrease in Apo B 23 but add on Alirocumab arm showed significantly higher reduction in ApoB. For selection of candidates for PCSK9 inhibitors, it is highly beneficial for patients who have ASCVD with LDL-C ≥ 140mg/dl or LDL-C ≥ 100mg/dl for patients who are at high risk of retracting ASCVD. 29 The safety and adverse effect profile of Alirocumab was found to be similar to that of Ezetimibe, hence Alirocumab can be effectively used instead of Ezetimibe in statin intolerant patients. 30 The treatment emergent adverse effects and serious adverse events are comparable with the previous studies.
Researchers have studied the various biological pathways underlining the lipid pathways, which includes association of males and the relation between PCSK9 and lipoprotein sub fractions and this interaction, may be attributed to a novel mechanism for gender disparity. 31 However this needs further exploration into the field. The major limitation of this review is thes mall number of studies are included in the study. In some studies, the specifics of the baseline statins are not mentioned and there is no data on the adherence of the statins. This can cause information bias in the analysis. Another important limitation is that, as the drug is just few years into the market, there are not much post marketing data available for the drug.
CONCLUSION
This review states that there is additional LDL-C reduction when Alirocumab is added to baseline statins hence reducing the cardiovascular risk significantly. It was well established that this reduction due to Alirocumab is independent by type and dose of statins as compared to placebo. But as the dose of statins increases (high intensity) the degree of LDL-C reduction decreases. But high intensity statin as well as PCSK9 inhibitors are said to decrease CVD risk, hence further research is required to refine this concept. Research on PCSK9 inhibitors should be extended to explore its long term effects emphasizing on the cardiovascular morbidity and mortality.
